Drug Trial Radar · NCT06615908
Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
May 27, 2025
Primary completion
Jun 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- University of CalgaryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of British Columbia
- First posted
- Sep 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized controlled trial is to evaluate the safety, feasibility, and efficacy of psilocybin assisted therapy as an intervention to reduce symptom burden in adult patients (aged 18-65) with persisting symptoms after concussion (PSaC). This trail will test the following 2 aims: AIM 1 : To test the safety and feasibility of an active psilocybin-assisted psychotherapy to an active control for patients with PSaC. AIM 2: To evaluate the efficacy of an active psilocybin-assisted psychotherapy compared to an active control as a treatment for PSaC. Participants will be asked to: * Complete a 2-part screening process * Attend a baseline assessment * Complete a psychoeducation preparation session(s) * Attend psilocybin administration session (receive high dose \[25mg\] or low dose psilocybin \[1mg\]) * Complete 5 weekly sessions of Acceptance and commitment therapy (ACT) * Repeat outcome measures at 1-week, 4 weeks, 3 months, and 6 months post-psilocybin administration (online only at 6 months).
Conditions
- Persisting Symptoms After Concussion
Interventions
PsilocybinDrug
See treatment arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Throughout study completion, an average of 6 months
- Study protocol efficacyTime frame: Throughout study completion, an average of 6 months
- Study protocol feasibilityTime frame: Screening, enrolment, intervention, and participation up to study end point (6-months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Calgary
Calgary, Alberta, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.